COSMOS

A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) Therapy

Guselkumab 100 mgCompletedCompletedPhase 3Open NCT03796858 on ClinicalTrials.gov ↗

Population

Loading…

Intervention

Loading…

Comparator

Loading…

Loading…

COSMOS · Trial Tracker · ComplyRx